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Translating genetic and preclinical findings 
into autism therapies 
Maria Chahrour, PhD; Robin J. Kleiman, PhD; M. Chiara Manzini, PhD
Introduction
 Over the past decade, major advances in genet-
ics and genomics have brought us closer to unraveling 
the molecular makeup of autism spectrum disorder 
(ASD). ASD is a constellation of neurodevelopmen-
tal abnormalities with social deficits and restrictive/re-
petitive behaviors as its core features. It affects about 
1% of the world population and is three to four times 
more prevalent in males than in females.1,2 Twin studies 
and a more recent large population-based epidemio-
logical study of roughly 2.5 million families have pro-
vided clear evidence for a genetic component of ASD 
and estimate the disease heritability at around 50% to 
95%,3,4 making it one of the most heritable of neuropsy-
chiatric disorders. Furthermore, in all these studies, the 
phenotypic concordance between monozygotic twins is 
incomplete, indicating that nongenetic environmental 
factors play a role in the etiology of ASD. The diver-
sity of contributing risk factors, degree of impairment, 
and expressed comorbidities found in individuals with 
ASD has created significant roadblocks to the identifi-
cation of therapeutic targets and successful execution 
of clinical trials. In this review, we highlight how human 
genetics, induced pluripotent stem-cell (iPSC)-derived 
neurons from patients, and murine models can be used 
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Autism spectrum disorder (ASD) is a complex neurode-
velopmental disorder characterized by social deficits and 
repetitive/restrictive interests. ASD is associated with mul-
tiple comorbidities, including intellectual disability, anxi-
ety, and epilepsy. Evidence that ASD is highly heritable 
has spurred major efforts to unravel its genetics, revealing 
possible contributions from hundreds of genes through 
rare and common variation and through copy-number 
changes. In this perspective, we provide an overview of 
the current state of ASD genetics and of how genetic re-
search has spurred the development of in vivo and in vi-
tro models using animals and patient cells to evaluate the 
impact of genetic mutations on cellular function leading 
to disease. Efforts to translate these findings into success-
ful therapies have yet to bear fruit. We discuss how the 
valuable insight into the disorder provided by these new 
models can be used to better understand ASD and de-
velop future clinical trials. 
© 2017, AICH – Servier Research Group Dialogues Clin Neurosci. 2017;19:335-343.
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to develop strategies to stratify patients. Cellular mod-
els from patient iPSCs can help identify common bio-
chemical pathways altered in patients, and mouse mod-
els replicating different human mutations can define 
common subsets of affected circuits.
ASD genetics: more patients, more genes
ASD is genetically complex and heterogeneous. To 
date, the identified genetic contributions to ASD in-
clude large chromosomal abnormalities, submicrosco-
pic deletions or duplications (copy number variants 
[CNVs]), and rare single-nucleotide variants (SNVs), 
both inherited and de novo (not present in either par-
ent). Common variation is estimated to contribute 
40% to 60% of ASD risk with many common variants 
each providing a very small effect size.5,6 Genome-
wide association studies (GWAS) remain underpow-
ered to yield reproducible results because of the ge-
netic heterogeneity of ASD patients.7 There is also an 
additive relationship between ASD risk contributed 
by rare variants and common polygenic variation.8 
Thus, cohorts on the order of tens of thousands of sub-
jects will be needed to identify all common variants, 
remaining mindful of the possible contribution from 
rare variants. 
 CNVs associated with ASD are highly heteroge-
neous, can be inherited9 or arise de novo,10 and are not 
specific to the core ASD phenotypes, but are rather as-
sociated with a wide range of neuropsychiatric and neu-
rodevelopmental phenotypes.11 The majority of CNVs 
have very low recurrence in ASD, and a specific CNV 
can often be unique to a single patient. Although the 
overall burden of de novo CNVs is higher in affected 
than in unaffected individuals, many of the same CNVs 
also occur in the unaffected individuals,12 making it 
difficult to determine which changes are likely to be 
disease-causing. The heterogeneity of CNV-associated 
phenotypes can also manifest within a single family as a 
result of unidentified modifiers.13
 To date, contributions from rare variants in over 
700 genes, both de novo and inherited, have been dem-
onstrated in ASD, highlighting its complex genetic ar-
chitecture. Early studies identified rare ASD-causing 
variants in established neurodevelopmental disease 
genes, including mutations in FMR1 (Fragile X syn-
drome; FXS), TSC (Tuberous Sclerosis Complex; TSC), 
MECP2 (Rett syndrome), and PTEN among others. 
Technological advances that enabled cost-effective se-
quencing of all protein-coding regions of the genome, 
termed whole exome sequencing (WES), allowed for 
the identification of coding variants in novel genes asso-
ciated with “idiopathic,” or nonsyndromic, ASD. WES 
studies demonstrated that rare de novo, as well as inher-
ited, SNVs contribute to disease risk—with causative de 
novo mutations identified in about 5% of ASD cases14-17 
and inherited complete loss of function (LoF) muta-
tions identified in around 5% of ASD cases.18 Network 
analyses using high-confidence ASD risk genes with 
de novo mutations reveal enrichment for genes encod-
ing chromatin modifiers (eg, CHD8, CHD2, ARID1B), 
synaptic signaling molecules (e.g. GRIN2B, GABRB3, 
SHANK3), early embryonic development players (eg, 
TBR1, DYRK1A, PTEN), and fragile X mental retarda-
tion protein (FMRP) targets.19-21 Many of these genes 
control transcriptional or signaling cascades that affect 
multiple cellular processes.22 Understanding how gene 
mutations in different networks converge on disrupted 
pathways will define how cases can be stratified for 
clinical trials and treatment. For example, if widespread 
impairments in Wnt and/or AKT/mTOR signaling  sig-
naling23,24 are identified in a range of ASD cases, such 
patients could be sorted into related treatment groups.
 The overall impact of rare inherited variants on 
ASD risk has not been quantified comprehensively, 
since current studies do not take into account possible 
contributions from missense variants, whose possible 
functional impact is difficult to measure. Studies focus-
ing on cohorts of both consanguineous and nonconsan-
guineous families have shown that rare recessive ASD 
mutations display similar heterogeneity in molecular 
pathways as shown by de novo mutations. Examples 
of ASD genes with recessive LoF mutations identified 
in families with ASD, intellectual disability, and other 
neurological and behavioral symptoms include CNT-
NAP2 24, SLC9A9/NHE9 25, BCKDK 26, and CC2D1A.28 
Some of the established recessive ASD mutations are 
hypomorphic alleles (retaining partial activity) of genes 
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whose complete inactivation causes severe neurologi-
cal syndromes.29 Examples of hypomorphic missense 
variants include those in AMT (encoding aminometh-
yltransferase), PEX7 (encoding peroxisomal biogenesis 
factor 7), and VPS13B (encoding vacuolar protein sort-
ing 13 homolog B)  that were identified in consanguine-
ous families with ASD. Complete LoF of these genes 
leads, respectively, to nonketotic hyperglycinemia, rhi-
zomelic chondrodysplasia punctata, and Cohen syn-
drome.29 UBE3B is another example of a candidate 
ASD gene in which a missense variant was identified30 
and was subsequently associated with a syndrome of in-
tellectual disability, lack of speech, and microcephaly.31 
Similar to the spectrum and heterogeneity of ASD-
associated CNVs, rare SNVs in “nonsyndromic” ASD 
genes can be associated with additional neurodevelop-
mental phenotypes. Thus, mutations in syndromic genes 
can also contribute to nonsyndromic ASD. 
 More recent work has focused on whole genome se-
quencing (WGS) in ASD cohorts to allow interrogation 
of the remaining (approximately) 99% of the genome 
that is not covered by WES. These efforts identified de 
novo CNVs and SNVs in coding regions of the genome 
that were missed by earlier WES studies, as well as vari-
ants in new candidate ASD genes.32 In addition, they 
suggest a role in ASD risk for de novo variants within 
noncoding regulatory regions of the genome.33,34 The 
noncoding variants mapped primarily to the untrans-
lated regions (UTRs) of genes and active cis-regulatory 
elements.33,34 WGS also suggested a role for paternally 
inherited structural variants affecting promoter regions 
and UTRs.35
 Large-scale sequencing efforts have contributed sig-
nificantly to our understanding of the complex genetic 
architecture of ASD and have begun to define specific 
molecular pathways and neuronal circuits disrupted in 
ASD patients with common genetic etiologies. The field 
is moving toward study of larger cohorts by partnering 
with families, clinicians, researchers, and community or-
ganizations. One such effort is the Simons Foundation 
Powering Autism Research for Knowledge (SPARK), 
which aims to build a cohort of 50 000 individuals with 
ASD. A second collaboration between Autism Speaks, 
Google, and Toronto’s SickKids Hospital has been 
named MSSNG, and will perform WGS in 10 000 ASD 
families. Future efforts must focus on high-throughput 
functional validation to assess the impact of identified 
variants on protein function and phenotype develop-
ment, particularly for missense variants. Furthermore, 
our understanding of how multiple variants might act in 
concert within an individual and the risk from noncod-
ing variation and gene by environment interactions are 
still in their infancy.
Preclinical studies in rodents: defining the 
circuitry controlling behavior
Modeling dysfunction in rodents has proven useful for 
understanding the impact of mutations associated with 
neuropsychiatric disorders and for testing possible ther-
apies before use in human studies.36,37 Animal models 
of human disorders are expected to meet multiple cri-
teria to be considered valid. They need to recapitulate 
the mechanism triggering the disorder, such as a gene 
mutation (construct validity), reproduce the symptoms 
(biochemical, histological, behavioral) of the disorder 
(face validity), and respond to pharmacological inter-
ventions as humans would (predictive validity).37,38 De-
fining to what extent an animal model of ASD is valid 
has been difficult.
 A primary hurdle in modeling ASD in mice is that 
there are no molecular diagnostic measures, eg, a simple 
blood test such as blood sugar for diabetes, or a histo-
logical readout such as neurofibrillary tangles for Al-
zheimer disease. The presence of the disorder must be 
tested behaviorally in patients. Thus, ethologically ap-
propriate paradigms for rodent or other animal behav-
ior required significant model development to ensure 
appropriate translation of results. To this end, multiple 
tests for the core features of ASD—sociability and re-
petitive behaviors—have been developed for use in 
conjunction with tests of cognitive deficits and anxiety, 
which are frequently comorbid.36 Excellent primers 
with the description of recommended behavioral test 
batteries for models of ASD and developmental delay 
have been published.39,40 Briefly, social function is stud-
ied by measuring social preference via interaction and/
or sniffing time in the following situations: (i) between 
animals, either stranger or previously encountered, 
in the three-chamber test; (ii) between a male and a 
stranger receptive female in mating-related interac-
tions; (iii) between young littermates in social play41; or 
(iv) with bedding from strangers or cage mates in the 
social-conditioned place preference (sCPP) test.42 
 Repetitive behaviors and restricted interests can be 
measured in rodents by measuring instinctual behav-
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iors, such as grooming and digging.43 Changes in self- 
and reciprocal grooming are a good example of normal 
behaviors that can become exaggerated to the point of 
shaving (barbering) or injury that is severe enough to 
lead to ulcerative lesions. Digging behavior is used as a 
proxy for compulsive behavior in obsessive-compulsive 
disorder (OCD) models, and the same paradigms are 
applied in ASD. One caveat of digging tests is that in-
creased digging is also linked to increased anxiety,44 and 
it is difficult to determine intent to confirm that the be-
havior is in fact excessive and compulsive, as opposed 
to recreational or shelter seeking. Finally, animal mod-
els of ASD have demonstrated comorbid anxiety and 
cognitive deficits that can include impairment in fear 
memory, cognitive flexibility, memory acquisition, and 
retention across different contexts as measured with 
well-established paradigms.45-47 
 Mouse models with construct validity, ie, engineered 
to carry the same genetic mutation found in humans, 
have presented constellations of behavioral impair-
ments that partially overlap with the human condi-
tion. As the number of mouse lines with ASD gene 
mutations is increasing, several comprehensive reviews 
have been published to summarize and compare find-
ings,38,39,48 often highlighting the variability in outcomes. 
As with patients, there is not a single clear combina-
tion of behavioral deficits caused by mutations in ASD 
genes. Each mouse line can present with a distinct sub-
set of social and cognitive deficits, and/or anxiety and 
repetitive behaviors. However, as different mouse lines 
only partially reflect the features of the human disor-
der, it is difficult to establish face validity. A recent ex-
ample of this variability comes from four mouse lines 
with heterozygous mutations in Chd8, a gene where 
frequent LoF de novo mutations have been identified 
in ASD.21 Mild social deficits with fewer and longer so-
cial encounters were identified in one study,49 normal 
interaction with strangers, but no memory of a previ-
ously encountered mouse in the three-chamber test, in 
another line,50 whereas comprehensive sociability anal-
ysis found no deficits in a different mouse.51 Additional 
inconsistencies were found in anxiety and cognitive 
performance.49-51 The type of genetic mutation, genetic 
background, and experimental conditions could be re-
sponsible for heterogeneity. Even in disorders like FXS 
and TSC with established mouse models for syndromic 
ASD,52 translation of preclinical work into clinical trials 
has been challenging.
 These results imply limited predictive validity for 
murine models and have called into question the pre-
clinical use of mice for modeling features of ASD tested 
in clinical trials. Moreover, they have revealed signifi-
cant shortcomings in our knowledge of the molecular 
pathways and circuits that regulate behavior in rodents 
and humans. We have barely begun to scratch the sur-
face in understanding the circuits involved in the vari-
ous social paradigms in the mouse, and it remains un-
clear how tests for repetitive behaviors used to model 
obsessive-compulsive behavior will translate to ASD. 
Additional behavioral tests may need to be developed 
to complement the available ones to reflect other as-
pects of ASD. Importantly, new assays must demon-
strate conservation of underlying molecular processes 
and circuits that are responsible for the similar function 
in the human brain. Other components of social inter-
action, such as cooperation, reciprocity, and empathy 
may be more relevant to the human disorder, and could 
be possible to assay in mice and rats.53 
 Despite these uncertainties, mouse models have 
been useful in dissecting how specific circuits are regu-
lated and altered by mutations in ASD genes. One ex-
ample is an elegant analysis of the mechanisms involved 
in sCPP showing that the preference for bedding linked 
to social experiences with cage mates depends on the 
reward circuitry in the nucleus accumbens (NAcc) reg-
ulated by both oxytocin and serotonin.54 These findings 
demonstrate a strong component of reward in remem-
bering the location of a social encounter, and oxytocin 
has been shown to modulate NAcc connectivity in social 
motivation and perception tasks in children with ASD.55 
Mouse studies have also implicated brain regions that 
were not traditionally thought to be involved in social 
behavior, such as the cerebellum. Heterozygous remov-
al of Tsc1 or Tsc2 in cerebellar Purkinje cells affects 
social behavior.52,56 Comparison of multiple ASD mod-
els has shown deficits in cerebellar circuits involved in 
sensory learning and integration, revealing that sensory 
processing in the cerebellum could be a shared deficit 
across multiple types of mutations.57 
 In summary, work in mice has made strong inroads 
in understanding how specific genetic mutations alter 
cellular function, synaptic transmission, and behavior, 
but coordinated and consistent large-scale compari-
sons of mutations in multiple genes using consistent 
experimental conditions is necessary. New behavioral 
tests may also be important to unravel the intricacies of 
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ASD. As behavioral studies have been often performed 
in males, particular attention should be placed in com-
paring males and females in animal models of ASD. 
Baseline behavioral sex-differences must be considered 
during interpretation of results, as well as sex-specific 
changes in mutant mice, leading to the identification of 
possible models of sex bias.58 
Patient-derived neurons point to common 
cellular and biochemical pathways
Genetics and animal models can provide information 
about the developmental risk factors contributing to 
ASD, but do not necessarily reveal which therapeutic 
targets will improve symptoms after a lifetime of cel-
lular and circuit-driven adaptations to altered neural 
function. Patient-derived neurons prepared from iPSCs 
can be used to identify drug targets and patient strati-
fication approaches based on common cellular pheno-
types and biochemical pathways. Study of iPSC-derived 
neurons from syndromic ASD patients has highlighted 
impairments of neural development including prolif-
eration, differentiation, and synapse formation.59 These 
dysfunctional cellular processes probably contribute to 
the changes in neural connectivity described in the con-
text of rodent models and patients. Phenotypes are of-
ten associated with disturbances of signal transduction 
cascades that include mTOR,60 AKT, extracellular-sig-
nal-regulated kinase (ERK),61 and/or Wnt signaling.62 
In patient-derived neurons from idiopathic autism, 
evidence has been found for disturbances in synaptic 
connectivity and function, with changes in expression 
of ASD-associated genes, including voltage-gated ion 
channels.63 
 Through use of patient-derived neurons with spe-
cific molecular deficits, investigators can identify tar-
geted therapeutic hypotheses. For example, patient-
derived excitatory neurons from Phelan-McDermid 
syndrome (PMDS) are haploinsufficient for SHANK3 
and display defects in synaptic transmission and mem-
brane resistance that was corrected by treating neurons 
with insulin-like growth factor 1 (IGF1).64 IGF1 treat-
ment was hypothesized to accelerate the maturation of 
patient-derived excitatory synapses lacking SHANK3 
into more mature synapses that are no longer depen-
dent upon SHANK3 because they contain mature ex-
pression of postsynaptic density protein 95 (PSD95) 
and N-methyl-d-aspartate (NMDA) receptors.64 This 
human developmental sequela was not apparent in mu-
rine preparations and may not have been recognized as 
a potential therapeutic approach if rodent models had 
been studied exclusively. Furthermore, studies of pre-
cisely engineered human neurons bearing heterozygous 
or homozygous loss of SHANK3 found that the previ-
ously observed increases in input resistance in PMDS 
neurons may be attributable to an impaired Ih current 
that is mediated by hyperpolarization-activated cyclic 
nucleotide (HCN)-gated channels.65 The finding that 
PMDS phenotypes are mimicked in control neurons 
with inhibitors of Ih raises the possibility that Ih channel 
potentiators could be a possible druggable target for 
neurodevelopmental disorders that exhibit impaired Ih 
currents.65 It is worth noting that rodent models of FXS 
also exhibit dysregulation of h-channel subunits and 
have impaired homeostatic h-channel plasticity.66 Other 
disorders that impinge on pathways producing deficits 
in maturation of glutamatergic synapse formation might 
yield overlapping subsets of patients that could benefit 
from similar therapeutic strategies. The development of 
techniques that promote rapid transdifferentiation67 of 
patient cells into neurons could, theoretically, allow for 
prospective stratification of idiopathic ASD patients for 
future clinical trials on the basis of properties of their 
transdifferentiated neurons.
 Modeling neurodevelopmental disorders through 
use of human neurons in vitro is creating a valuable sub-
strate for new phenotypic drug screens. The challenges 
of working with iPSC-derived models have been docu-
mented extensively elsewhere68 and include managing 
variability, determining which neuronal cell type and 
stage of development to model, and most importantly, 
determining what types of cellular end points would 
translate to measurable end points in patients. Use of 
chemical libraries with annotated mechanisms of action 
or US Food and Drug Administration (FDA)-approved 
drugs to identify new targets and repurposing opportu-
nities for approved medicines will be especially pow-
erful. Although access to high-quality small-molecule 
libraries with well-annotated mechanisms of action can 
be challenging for academic investigators, these files 
are available from many industry collaborators. Find-
ing mutually acceptable terms for agreements between 
academic and industry technology transfer offices is 
often a hurdle. Furthermore, limited access to pharma-
cokinetic data and expertise needed to experimentally 
measure drug levels in animal models remains a criti-
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cal roadblock to conducting meaningful translational 
follow-up studies in academic settings and requires new 
infrastructure.69 
Stratification of patients for clinical trials 
varies by risk factors and therapeutic target
The heterogeneity of genetic and molecular deficits 
found in ASD suggests that a one-size-fits-all therapy 
is unlikely. Matching the correct subset of patients to 
each potential treatment and finding outcome mea-
sures that capture the benefit associated with efficacy 
is the biggest challenge to attracting the interest of 
commercial drug developers to ASD. Use of genetics 
as a stratification approach for clinical trials requires 
that the genetic perturbation confer a high degree of 
risk to the individual (Figure 1). Monogenic disorders 
such as FXS, Rett syndrome, or TSC have been chosen 
as the best candidates for subsets of autism on the ba-
sis of the assumption that a common genetic defect will 
trigger similar compensatory changes. However, even 
in monogenic disorders with high penetrance, such as 
FXS, there is a broad range of variation in genotype 
and phenotype driven by the number of CGG repeats 
and epigenetic methylation of the FMR1 promoter. 
Clinical trials for FXS have highlighted that there re-
mains significant variability in the response of individ-
ual patients to candidate treatments, even when all pa-
tients have the same syndrome.70-73 A comprehensive 
and thoughtful review of clinical trials conducted in 
FXS recently highlighted many of the challenges faced 
by investigators to build the infrastructure to recruit, 
assess, and enroll patients for the early clinical trials 
in FXS.74 The remaining challenge for syndromic ASD 
will be to identify measures that accurately capture 
benefit for each syndrome and relate them to preclini-
cal data sets. 
 Preclinical data sets collected with candidate drugs 
for FXS often use Fmr1-knockout mice to evaluate 
efficacy against phenotypes observed in mice, which 
only exhibit a partial overlap with features of the hu-
man condition.75 Many preclinical studies focused on 
reversal of robust mouse deficits observed in measures 
of hippocampal synaptic plasticity (long-term depres-
sion [LTD]) and seizure behavior (audiogenic sei-
zures), which provided little insight into what the most 
likely benefit would be for a human patient, given that 
seizures are not a problem for most FXS patients.76 
Early clinical trials for FXS used preexisting outcome 
measures, including the Aberrant Behavior Checklist 
(ABC) and the Clinical Global Impressions (CGI) 
scale. Several subsequent studies conducted in small 
patient populations focused on select subscales of 
the ABC and expanded the number of clinical scales 
evaluated in the hope of finding a subset of sensitive 
measures that would support larger, pivotal trials 
needed for drug approval.74 Dedicated efforts to de-
velop better clinical tools that are tailored to measure 
outcomes for these genetically defined patient popu-
lations should improve future success for syndromic 
autism.77 
 Given that most ASD patients do not have a highly 
penetrant genetic mutation, nonsyndromic clinical tri-
als will require a biochemical or circuit-driven biomark-
er to stratify patients into more homogeneous subsets 
(Figure 1). For example, emerging evidence shows that 
the activity-dependent refinement of cerebellar circuits 
is critical to development of appropriate social behavior 
in rodent models of ASD; this finding is further support-
ed by human studies that show injury to the cerebellum 
early in development is among the highest risk factor 
for developing ASD, and developmental malforma-
tions are frequently reported in ASD brain (reviewed 
by Wang and colleagues78). Visual-motor abnormalities 
in saccadic eye movements reported in ASD patients 
support the hypothesis that functional integrity of cer-
ebellar circuits is impaired in visually guided tasks in 
many individuals with ASD.79 As mentioned above, se-
lective removal of Tsc1 and Tsc2 in cerebellar Purkinje 
cells is sufficient to replicate ASD-like deficits in social 
approach, social interaction, and water maze reversal 
learning.52,56 Furthermore, sensory integration deficits 
in the cerebellum are common to mouse models reca-
pitulating inherited and de novo mutations and CNVs 
(MECP2, TSC1, SHANK3, CNTNAP2, and 15q11-13 
duplication).57 
 Cerebellar circuitry is highly conserved between 
rodents and humans, and it can be monitored func-
tionally in animals and humans of all ages through use 
of classical tests of associative eyeblink conditioning. 
Associative eyeblink conditioning in normal human 
babies exhibits a range of efficiency that can be de-
tected as early as at 1 month of age. The efficiency of 
an individual baby’s performance predicts the emer-
gence of social behavior measures at 5 and 9 months 
of age.80 Furthermore, conditioned eyeblink response 
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has been reported to be impaired in ASD subjects.81,82 
Similarly, saccade adaptation abnormalities have been 
reported in ASD subjects who adapt slower and dem-
onstrate more variability than healthy controls.79,83 It is 
possible that subsets of ASD patients who exhibit cer-
ebellar circuit dysfunction could represent a similarly 
impaired subset of idiopathic ASD patients that would 
benefi t from pharmacological treatments that improve 
activity-dependent plasticity in this circuit during ear-
ly postnatal development, regardless of their genetic 
risk factors. 
 Additional ASD patient subsets defi ned by mini-
mally invasive and highly translatable circuit biomark-
ers will be needed in order to design clinical trials for 
more patients. Consideration for the cost and ease of 
screening patients for inclusion criteria, as defi ned 
by new stratifi cation biomarkers, will be a critical el-
ement to paving a path to clinical trials, particularly 
those conducted over many different sites. For exam-
ple, electroencephalogram (EEG)-based measures of 
hemispheric connectivity applied to naturally sleeping 
children84 may have biomarker potential for subsets 
of children with similar defi cits in connectivity. EEG 
technology is commonly available at a broad range of 
medical centers and is not cost-prohibitive for large 
clinical trials. 
Filling the pipeline
Identifi cation of new drug targets to treat ASD is not 
enough to attract commercial drug development to 
work in this area. A viable path for conducting hypoth-
esis-based clinical trials must be developed for each 
patient subset. As additional genes are identifi ed that 
confer risk for ASD, preclinical models that evaluate 
their impact on human neurons in vitro and genetically 
engineered mice in vivo will expand our understanding 
of common phenotypes. The advent of CRISPR/Cas9 
(clustered regularly interspaced short palindromic 
repeats/CRISPR-associated protein-9 nuclease) ge-
nome engineering has further opened up the possibil-
ity to study animal species with more complex social 
behaviors, such as prairie voles or nonhuman primates. 
Unraveling the mechanistic basis for circuit-level dys-
function across models and identifying the expression 
of translatable biomarkers that refl ect homogenous pa-
tient subsets will be required to stratify patient popula-
tions for future clinical trials. o
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 Figure 1.  Strategies for clinical trial stratifi cation. The heterogene-
ity inherent in autism spectrum disorder (ASD) will require 
separating patients into more homogeneous subsets to test 
specifi c therapeutic hypotheses. (A) Stratifi cation approach-
es can be developed on the basis of genetic mutations, bio-
chemical pathways, or neural circuits to yield more homoge-
neous populations. Stratifi cation based on human genetics 
will require that the genes used to narrow the range of the 
population confer a very high degree of risk for ASD. This 
is the case with monogenic disorders or very highly pene-
trant variants, such as TSC1/2, FMR1, MECP2, or CHD8 (left 
panel). Stratifi cation based on biochemical pathways will be 
useful to create subgroups of patients with dysregulation of 
specifi c signaling cascades, such as mTOR, Wnt signaling, or 
impaired ion-channel function that are due to dysregulation 
from a wide range of de novo or weakly penetrant muta-
tions that impinge on a common pathway (middle panel). 
(B) Monogenic/syndromic and nonsyndromic ASD may re-
quire different strategies for stratifi cation. Nonsyndromic 
ASD is caused by a mixture of genetic and environmental 
factors that will be best stratifi ed for clinical trials by moni-
toring the dysregulation of specifi c circuits linked to key 
symptomatic domains. AKT/mTOR, protein kinase B/mecha-
nistic target of rapamycin; CHD8, chromodomain helicase 
DNA-binding protein 8; FMR1, fragile X mental retardation 
protein; MECP2, methyl CpG binding protein 2; TSC1/2, tu-
berous sclerosis complex
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Trasladar los hallazgos genéticos y preclínicos a 
las terapias del autismo
El trastorno del espectro autista (TEA) es un complejo 
trastorno del neurodesarrollo caracterizado por déficits 
sociales e intereses repetitivos/restrictivos. El TEA se aso-
cia con múltiples comorbilidades, incluyendo discapaci-
dad intelectual, ansiedad y epilepsia. La evidencia de la 
alta heredabilidad del TEA ha estimulado los mayores 
esfuerzos para descifrar su genética, revelando posibles 
contribuciones de cientos de genes a través de variacio-
nes raras y comunes, y de la variabilidad en el número 
de copias. Desde esta perspectiva se entrega una pa-
norámica del estado actual de la genética del TEA y de 
cómo la investigación genética ha estimulado el desa-
rrollo de modelos in vivo e in vitro que emplean células 
de animales y de pacientes para evaluar el impacto de 
las mutaciones genéticas en la función celular que lleva 
a la enfermedad. Aún no han dado frutos los esfuerzos 
realizados en la traducción de estos hallazgos en tera-
pias exitosas. Se discute cómo se puede emplear la valio-
sa información acerca del trastorno, proporcionada por 
estos nuevos modelos, para una mejor comprensión del 
TEA y para desarrollar futuros ensayos clínicos.     
    
Traduire les résultats précliniques et génétiques 
en traitement de l’autisme
Le trouble du spectre de l’autisme (TSA) représente 
un trouble complexe neurodéveloppemental caracté-
risé par des déficits sociaux et des intérêts répétitifs et 
restreints. Les comorbidités associées au TSA sont mul-
tiples, comme la déficience intellectuelle, l’anxiété et 
l’épilepsie. La transmissibilité élevée démontrée du TSA 
a encouragé des efforts importants pour décoder sa gé-
nétique, des centaines de gènes étant potentiellement 
impliqués par des variations rares et courantes et par la 
variabilité du nombre de copies. Dans cette perspective, 
nous présentons un aperçu de l’état actuel  de la géné-
tique du TSA et de la façon dont la recherche génétique 
a stimulé le développement de modèles in vivo et in vitro 
utilisant des cellules humaines et animales pour évaluer 
l’incidence de mutations génétiques sur les fonctions 
cellulaires responsables de la maladie. Les efforts pour 
traduire ces résultats en traitements efficaces n’ont pas 
encore porté leurs fruits. Nous expliquons comment les 
informations précieuses apportées par ces nouveaux 
modèles peuvent être utilisées pour mieux comprendre 
le TSA et développer de futurs essais cliniques. 
